VC UPDATE: Polaris closes $450m fund in biotech-friendly US market

Polaris Partners closed its seventh venture capital fund, raising $450m to finance private technology and health care companies in an environment that's increasingly friendly to VC investments generally and biotechnology investments specifically. The National Venture Capital Association (NVCA) reported in October that across the biotech, high-tech, finance and retail industries VC firms raised $23.8bn for new funds through the third quarter of 2014. That was more than the venture capital industry raised in any 12-month period dating back to 2009 and this year is on track to beat the $25.1bn total in 2008. How is that money and cash from prior fundraising years being invested in the life science industry in 2014? About $5.9bn in venture capital was invested in biotech and medical device companies during third quarter, according to the MoneyTree report compiled by NVCA and PricewaterhouseCoopers (PwC) with data from Thomson Reuters. "For the first nine months of the year, investment in the life sciences has almost touched $6bn, which is close to the $6.7bn invested for the full year in 2013," PwC life sciences partner Greg Vlahos said in a recent third quarter review of biotech and medical device venture capital. "Overall 2014 is expected to be one of the strongest years for life sciences investments, especially for biotech." Third quarter VC investment in biotech companies jumped 7% year-over-year to $1.05bn (although the number of deals slipped by 13% to 110), including $601m for early-stage opportunities. The nearly $4bn in biotech venture capital raised through September puts the sector well on its way to exceeding the $4.7bn raised in 2013 (scripintelligence.com, 26 October 2014). Biotech VC investment has been helped by returns from recent initial public offerings and acquisitions. Polaris, despite its focus on both health care and technology, has been an active supporter of biotech companies. The VC firm recently participated in a $53m Series B round for Syros Pharmaceuticals, a $30m Series B round for Visterra, and a $20m Series A for Scholar Rock (scripintelligence.com, 31 October, 2 October and 15 September 2014). Polaris joins the ranks of other biotech VC investors that raised or are about to close new funds in 2014, including Versant Ventures, which will get up to $25m from Bayer HealthCare for its new $300m-plus fund (scripintelligence.com, 6 November 2014). Biotech companies that recently closed venture capital and other private financing deals include Intellia Therapeutics, Renova Therapeutics and N30 Pharmaceuticals. Company Technology Financing news  Intellia Therapeutics; Cambridge, Massachusetts   The newly formed company will develop therapeutic products that use CRISPR-Cas9 technology for gene editing and repair in a wide variety of diseases and indications.   Intellia raised $15m in a Series A venture capital round led by Atlas Venture and Novartis.   Renova Therapeutics; San Diego, California   Developing gene therapies for congestive heart failure (CHF) and other chronic diseases, Renova is running a 56-patient, Phase I/II clinical trial for its lead CHF gene therapy candidate under a public-private partnership with the National Institutes of Health. The company's preclinical pipeline includes a second-generation CHF therapy and a type 2 diabetes product candidate.   Five-year-old Renova raised a $7.52m Series C round from high-net-worth individuals. The company also made a new appointment to its board of directors: Daniel Bradbury, who was CEO of Amylin Pharmaceuticals when it was acquired by Bristol-Myers Squibb for $7bn in 2012. Mr Bradbury currently is a managing member of the life sciences consulting and investment firm BioBrit.   N30 Pharmaceuticals; Boulder, Colorado   N30 is developing the oral drug N91115, an S-nitrosoglutathione reductase (GSNOR) inhibitor, to treat cystic fibrosis (CF). After completing a Phase I clinical trial in healthy volunteers, the company is running two Phase I trials with CF patients who have a genetic mutation that's present in about 90% of people with the lung disease. The Cystic Fibrosis Foundation previously provided funding for N9115 (scripintelligence.com, 21 November 2014). New investors Wellington Management, RA Capital Management, Jennison Associates, Rock Springs Capital Management and Sabby Management joined existing investor Deerfield Management in a $30m mezzanine financing round. 

Polaris Partners closed its seventh venture capital fund, raising $450m to finance private technology and health care companies in an environment that's increasingly friendly to VC investments generally and biotechnology investments specifically.

The National Venture Capital Association (NVCA) reported in October that across the biotech, high-tech, finance and retail industries VC firms...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Alimentary/Metabolic

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By 

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

More from Therapy Areas

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Moderna’s Spikevax Wins Pediatric Approval, But With Narrower Label

 

The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By 

Lynkuet will compete with Astellas's Veozah/Veoza